Oral dextrose gel for hypoglycemia in a well-baby nursery: a baby-friendly initiative

Mansi Batra,Kelechi Ikeri,Michelle Blake,Genevieve Mantell,Ramachandra Bhat,Michael Zayek

DOI: https://doi.org/10.1038/s41372-024-02114-y

2024-09-15

Journal of Perinatology

Abstract:To assess the impact of oral dextrose gel (ODG) treatment on NICU admission rates for hypoglycemic infants in a well-baby nursery.

pediatrics,obstetrics & gynecology

What problem does this paper attempt to address?

The impact of implementation of oral dextrose gel on the incidence of multiple hypoglycemia events in the well newborn nursery

Lakshmy Vaidyanathan,Davika Reid,Yingchao Yuan,Alan Groves

DOI: https://doi.org/10.1038/s41372-024-02032-z

2024-06-27

Journal of Perinatology

Abstract:Evaluate the impact of 40% oral dextrose gel (DG) for management of neonatal hypoglycemia (NH) on the incidence of multiple hypoglycemic events in the well-baby nursery.

pediatrics,obstetrics & gynecology
Prophylactic dextrose gel use in newborns at risk for hypoglycemia

Venkatasai Devarapalli,Makenzie Niven,Jared Canonigo,Beverly Spray,Indirapriya Avulakunta,Jared Beavers,Jennifer Andrews,Vikramaditya Dumpa

DOI: https://doi.org/10.1038/s41372-024-02133-9

2024-10-04

Journal of Perinatology

Abstract:To assess the impact of prophylactic dextrose gel on short-term outcomes in infants at risk for hypoglycemia.

pediatrics,obstetrics & gynecology
Evaluation of oral dextrose gel for prevention of neonatal hypoglycemia (hPOD): A multicenter, double-blind randomized controlled trial

Jane E. Harding,Joanne E. Hegarty,Caroline A. Crowther,Richard P. Edlin,Gregory D. Gamble,Jane M. Alsweiler,,

DOI: https://doi.org/10.1371/journal.pmed.1003411

2021-01-28

PLoS Medicine

Abstract:Background Neonatal hypoglycemia is common and can cause brain injury. Buccal dextrose gel is effective for treatment of neonatal hypoglycemia, and when used for prevention may reduce the incidence of hypoglycemia in babies at risk, but its clinical utility remains uncertain. Methods and findings We conducted a multicenter, double-blinded, placebo-controlled randomized trial in 18 New Zealand and Australian maternity hospitals from January 2015 to May 2019. Babies at risk of neonatal hypoglycemia (maternal diabetes, late preterm, or high or low birthweight) without indications for neonatal intensive care unit (NICU) admission were randomized to 0.5 ml/kg buccal 40% dextrose or placebo gel at 1 hour of age. Primary outcome was NICU admission, with power to detect a 4% absolute reduction. Secondary outcomes included hypoglycemia, NICU admission for hypoglycemia, hyperglycemia, breastfeeding at discharge, formula feeding at 6 weeks, and maternal satisfaction. Families and clinical and study staff were unaware of treatment allocation. A total of 2,149 babies were randomized (48.7% girls). NICU admission occurred for 111/1,070 (10.4%) randomized to dextrose gel and 100/1,063 (9.4%) randomized to placebo (adjusted relative risk [aRR] 1.10; 95% CI 0.86, 1.42; p = 0.44). Babies randomized to dextrose gel were less likely to become hypoglycemic (blood glucose < 2.6 mmol/l) (399/1,070, 37%, versus 448/1,063, 42%; aRR 0.88; 95% CI 0.80, 0.98; p = 0.02) although NICU admission for hypoglycemia was similar between groups (65/1,070, 6.1%, versus 48/1,063, 4.5%; aRR 1.35; 95% CI 0.94, 1.94; p = 0.10). There were no differences between groups in breastfeeding at discharge from hospital (aRR 1.00; 95% CI 0.99, 1.02; p = 0.67), receipt of formula before discharge (aRR 0.99; 95% CI 0.92, 1.08; p = 0.90), and formula feeding at 6 weeks (aRR 1.01; 95% CI 0.93, 1.10; p = 0.81), and there was no hyperglycemia. Most mothers (95%) would recommend the study to friends. No adverse effects, including 2 deaths in each group, were attributable to dextrose gel. Limitations of this study included that most participants (81%) were infants of mothers with diabetes, which may limit generalizability, and a less reliable analyzer was used in 16.5% of glucose measurements. Conclusions In this placebo-controlled randomized trial, prophylactic dextrose gel 200 mg/kg did not reduce NICU admission in babies at risk of hypoglycemia but did reduce hypoglycemia. Long-term follow-up is needed to determine the clinical utility of this strategy. Trial registration ACTRN 12614001263684 .

medicine, general & internal
Effectiveness of hospital-based oral dextrose gel in prevention and treatment of asymptomatic newborns at risk of hypoglycemia

Rachaporn Rattanamalee,Pracha Nuntnarumit

DOI: https://doi.org/10.1080/14767058.2024.2341310

2024-04-16

The Journal of Maternal-Fetal & Neonatal Medicine

Abstract:Objective To evaluate the effectiveness of using hospital-based 40% dextrose gel (DG) in preventing and treating asymptomatic hypoglycemia in infants of diabetic mothers (IDM), large for gestational age (LGA), and macrosomic neonates.

obstetrics & gynecology
Clinical outcomes in newborns receiving glutose 15 versus sweet cheeks oral glucose gel for neonatal hypoglycemia

Karen Stanzo,Traci Szostek,Sujata Desai,Arpitha Chiruvolu

DOI: https://doi.org/10.1038/s41372-024-01896-5

2024-02-11

Journal of Perinatology

Abstract:A meta-analysis including two randomized controlled trials stated that using glucose gel as a treatment for neonatal hypoglycemia (NH) probably increases the correction of hypoglycemic events, decreases family separation, and increases exclusive breastfeeding rates [1]. Our group previously reported the glucose inconsistency within the tube of Glutose 15 (Paddock Laboratories, Minneapolis, MN), an oral glucose gel that is designed to treat hypoglycemia in adult diabetics but is also being used widely in the US to treat NH [2]. Thereafter, our hospital switched to the use of a new gel manufactured specifically for neonates, and packaged in pre-filled syringes, Sweet Cheeks (Dandle Lion Medical, Danbury, CT). Subsequently, our team reported inconsistency of glucose concentration within the syringe of Sweet Cheeks [3]. However, since the Sweet Cheeks syringe contains only about 1 to 2 doses, in contrast to approximately 11 doses in the tube of Glutose 15, the clinical significance of these findings is unknown. There are no studies comparing these two brands of glucose gel now commonly used in the US. The purpose of this study is to close this gap by comparing functional outcomes in newborns who were treated for NH using Glutose 15 to those given Sweet Cheeks. This is an IRB-approved, single-center, retrospective cohort study comparing otherwise healthy newborns over 35 weeks of gestation in the mother-baby unit who were treated for NH with Glutose 15 (July 1, 2020–February 11, 2021) with infants treated for NH with Sweet Cheeks (February 12, 2021–January 8, 2022). All infants who were immediately admitted to the NICU after birth were excluded. Except for the brand of glucose gel they received, all newborns who experienced NH received the same care including skin-to-skin contact with the mother, frequent blood glucose monitoring, and early feeding (Supplementary Fig. 1). When glucose gel was indicated, nurses used gauze to dry the newborn's mouth and then massaged 0.5 mL/kg of the gel into the buccal mucosa. Maternal and infant characteristics and outcomes were compared between the two cohorts. Analyses were performed utilizing IBM SPSS Version 29.

pediatrics,obstetrics & gynecology
Outcome at 4.5 years after dextrose gel treatment of hypoglycaemia: follow-up of the Sugar Babies randomised trial

Deborah L Harris,Greg D Gamble,Jane E Harding,CHYLD Study Group,Jane Harding,Jane M Alsweiler,Trecia A Wouldes,Gavin T L Brown,Christopher J D McKinlay,Benjamin Thompson,J Geoffrey Chase,Judith Ansell,Anne Jaquiery,Kelly Jones,Sapphire Martin,Christina McQuoid,Jenny Rogers,Heather Stewart,Anna Timmings,Anna Tottman,Kate Williamson,Arun Nair,Alexandra Wallace,Phil Weston,Nicola Austin,Jeremy Armishaw,Nicola Webster,Ross Haslam,Pat Ashwood,Lex Doyle,Kate Callanan,Ian Wright,Jessica Brosnahan,Ellen Campbell,Coila Bevan,Tineke Crawford,Kelly Fredell,Kate Sommers,Claire Hahnhaussen,Safayet Hossin,Karen Frost,Grace McKnight,Janine Paynter,Jess Wilson,Rebecca Young,Anna Gsell,Aaron Le Compte,Matthew Signal,Yannah Jiang,Tzu-Ying Sandy Yu

DOI: https://doi.org/10.1136/archdischild-2022-324148

Abstract:Objective: Dextrose gel is used to treat neonatal hypoglycaemia, but later effects are unknown. Design and setting: Follow-up of participants in a randomised trial recruited in a tertiary centre and assessed in a research clinic. Patients: Children who were hypoglycaemic (<2.6 mmol/L) recruited to the Sugar Babies Study (>35 weeks, <48 hours old) and randomised to treatment with 40% dextrose or placebo gel. Interventions: Assessment of neurological status, cognitive ability (Weschler Preschool and Primary Scale of Intelligence), executive function (five tasks), motor function (Movement Assessment Battery for Children-2 (MABC-2)), vision, visual processing (Beery-Buktenica Development Test of Visual Motor Integration (Beery VMI) and motion coherence thresholds) and growth at 2 years. Main outcome measures: Neurosensory impairment (cerebral palsy; visual impairment; deafness; intelligence quotient <85; Beery VMI <85; MABC-2 score <15th centile; low performance on executive function or motion coherence). Results: Of 237 babies randomised, 185 (78%) were assessed; 96 randomised to dextrose and 89 to placebo gel. Neurosensory impairment was similar in both groups (dextrose 36/96 (38%) vs placebo 34/87 (39%), relative risk 0.96, 95% CI 0.66 to 1.34, p=0.83). Secondary outcomes were also similar, except children randomised to dextrose had worse visual processing scores (mean (SD) 94.5 (15.9) vs 99.8 (15.9), p=0.02) but no differences in the proportion with visual processing scores <85 or other visual test scores. Children randomised to dextrose gel were taller (z-scores 0.18 (0.97) vs -0.17 (1.01), p=0.001) and heavier (0.57 (1.07) vs 0.29 (0.92), p=0.01). Conclusions: Treatment of neonatal hypoglycaemia (<2.6 mol/L) with dextrose gel does not alter neurosensory impairment at 4.5 years. However, further assessment of visual processing and growth may be warranted. Trial registration number: ACTRN1260800062392.
Midwife or doctor local opinion leader to implement a national guideline in babies on postnatal wards (DesIGN): protocol of a cluster-randomised, blinded, controlled trial

Jane Marie Alsweiler,Caroline A Crowther,Jane E Harding

DOI: https://doi.org/10.1136/bmjopen-2017-017516

IF: 3.006

2017-11-01

BMJ Open

Abstract:Introduction Neonatal hypoglycaemia is a common condition that can cause developmental delay. Treatment of neonatal hypoglycaemia with oral dextrose gel has been shown to reverse hypoglycaemia and reduce admissions to neonatal intensive care for hypoglycaemia. An evidence-based clinical practice guideline was written to guide the use of dextrose gel to treat neonatal hypoglycaemia in New Zealand. However, it is unclear what clinical discipline might most effectively lead the implementation of the guideline recommendations. Objective To determine if midwife or doctor local opinion leaders are more effective in implementing a clinical practice guideline for use of oral dextrose gel to treat hypoglycaemia in babies on postnatal wards. Methods and analysis A cluster-randomised, blinded, controlled trial. New Zealand maternity hospitals that care for babies born at risk of neonatal hypoglycaemia will be randomised to having either a local midwife or doctor lead the guideline implementation at that hospital. The primary outcome will be the change in the proportion of hypoglycaemic babies treated with dextrose gel from before implementation of the guideline to 3 months after implementation. Ethics and dissemination Approved by Health and Disability Ethics Committee: 15/NTA/31. Findings will be disseminated to peer-reviewed journals, guideline developers and the public. Trial registration number ISRCTN61154098 .

medicine, general & internal
Oral glucose gel in the prevention of neonatal hypoglycemia: A systematic review and meta-analysis

Meng-Qin Wang,Ya-Ning Zheng,Ying Zhuang

DOI: https://doi.org/10.1097/MD.0000000000036137

2023-12-01

Abstract:Background: Neonatal hypoglycemia (NH) is the most prevalent metabolic disorder in neonates and glucose gel in oral solution is a relatively new treatment option for NH. We aimed to determine whether oral glucose gel can prevent NH. Methods: We conducted an open literature search using PubMed, Embase, Cochrane Library, and Web of Science. We used relative risk as the statistical data, expressed each outcome effect as a 95% confidence interval, and conducted a heterogeneity test. If heterogeneity statistics indicated that I2 was ≥ 50%, the random effects model analysis was used; otherwise, the fixed effects model analysis was conducted, and sensitivity analyses were conducted for all outcomes. Results: In this review, we included a total of 10 studies involving 4801 neonates. Meta-analysis revealed that there were no significant differences between the preventive oral glucose gel group and the control group in terms of blood glucose concentration, glucose concentration 30 minutes after the first breastfeeding, length of stay, Bayley-III composite score, subsequent need for intravenous injection of glucose, 24-hour glucose > 50 mg/dL, separation from mother for treatment of hypoglycemia/admitted to neonatal intensive care unit for hypoglycemia, normoglycemia after 1 to 2 treatments, or normoglycemia after more than 2 treatments, breastfeeding at discharge, delayed feeding, neurosensory impairment, parental satisfaction, developmental delay, and seizure. The subsequent intake was significantly lower in the glucose gel group compared to the control group. Interpretation: The use of oral glucose gel as a preventative measure may not reduce the incidence of NH. In order to assess the efficacy of glucose gel in preventing NH, a more high-quality, large-sample, and rigorously designed randomized controlled trial is required.
Dextrose gel prophylaxis for neonatal hypoglycaemia and neurocognitive function at early school age: a randomised dosage trial

Xingyu Wei,Nike Franke,Jane M Alsweiler,Gavin T L Brown,Gregory D Gamble,Alicia McNeill,Jenny Rogers,Benjamin Thompson,Jason Turuwhenua,Trecia A Wouldes,Jane E Harding,Christopher J D McKinlay

DOI: https://doi.org/10.1136/archdischild-2023-326452

2024-02-02

Archives of Disease in Childhood - Fetal and Neonatal Edition

Abstract:Objective To investigate the effect of different doses of prophylactic dextrose gel on neurocognitive function and health at 6–7 years. Design Early school-age follow-up of the pre-hPOD (hypoglycaemia Prevention with Oral Dextrose) study. Setting Schools and communities. Patients Children born at ≥35 weeks with ≥1 risk factor for neonatal hypoglycaemia: maternal diabetes, small or large for gestational age, or late preterm. Interventions Four interventions commencing at 1 hour of age: dextrose gel (40%) 200 mg/kg; 400 mg/kg; 200 mg/kg and 200 mg/kg repeated before three feeds (800 mg/kg); 400 mg/kg and 200 mg/kg before three feeds (1000 mg/kg); compared with equivolume placebo (combined for analysis). Main outcomes measures Toolbox cognitive and motor batteries, as well as tests of motion perception, numeracy and cardiometabolic health, were used. The primary outcome was neurocognitive impairment, defined as a standard score of more than 1 SD below the age-corrected mean on one or more Toolbox tests. Findings Of 392 eligible children, 309 were assessed for the primary outcome. There were no significant differences in the rate of neurocognitive impairment between those randomised to placebo (56%) and dextrose gel (200 mg/kg 46%: adjusted risk difference (aRD)=−14%, 95% CI −35%, 7%; 400 mg/kg 48%: aRD=−7%, 95% CI −27%, 12%; 800 mg/kg 45%: aRD=−14%, 95% CI −36%, 9%; 1000 mg/kg 50%: aRD=−8%, 95% CI −29%, 13%). Children exposed to any dose of dextrose gel (combined), compared with placebo, had a lower risk of motor impairment (3% vs 14%, aRD=-11%, 95% CI −19%, −3%) and higher mean (SD) cognitive scores (106.0 (15.3) vs 101.1 (15.7), adjusted mean difference=5.4, 95% CI 1.8, 8.9). Conclusions Prophylactic neonatal dextrose gel did not alter neurocognitive impairment at early school age but may have motor and cognitive benefits. Further school-age follow-up studies are needed.

pediatrics
Diazoxide for Severe or Recurrent Neonatal Hypoglycemia

Don Laing,Eamon P. G. Walsh,Jane M. Alsweiler,Sara M. Hanning,Michael P. Meyer,Julena Ardern,Wayne S. Cutfield,Jenny Rogers,Gregory D. Gamble,J. Geoffrey Chase,Jane E. Harding,Christopher J. D. McKinlay

DOI: https://doi.org/10.1001/jamanetworkopen.2024.15764

2024-06-14

JAMA Network Open

Abstract:This randomized clinical trial investigates whether administration of early, low-dose oral diazoxide in neonates with severe or recurrent hypoglycemia reduces time to normoglycemia.

medicine, general & internal
Insulin infusion with parenteral nutrition in extremely low birth weight infants with hyperglycemia

Nancy D. Binder,Paula K. Raschko,Gerda I. Benda,John W. Reynolds

DOI: https://doi.org/10.1016/s0022-3476(89)80797-8

IF: 6.314

1989-02-01

The Journal of Pediatrics

Abstract:From Nov. 7, 1983, to Nov. 6, 1986, all infants with birth weight less than or equal to 1000 gm admitted to Oregon Health Sciences University who had persistent hyperglycemia and glycosuria were treated with graded insulin infusion while energy intake was increased to at least 100 kcal/kg/day (419 kilojoules/kg/day). The records of these infants were reviewed to define the clinical characteristics of infants likely to develop hyperglycemia and to see whether insulin administration would allow goals for energy intake to be met. There were 76 surviving infants; 34 received insulin and 42 did not. Treated infants were smaller (767 +/- 161 vs 872 +/- 98 gm; p = 0.0004), were more immature (26.8 +/- 1.4 vs 27.7 +/- 2.0 weeks; p = 0.0115), and required mechanical ventilation longer (28 +/- 19 vs 17 +/- 15 days; p = 0.0196). There were no significant differences between the groups at 3, 7, 10, or 14 days for intravenously administered glucose or for total nonprotein energy intake at 3, 7, 10, 14, 28, or 56 days. Treated infants achieved an intake of 100 kcal/kg/day (419 kilojoules/kg/day) at 15 +/- 8 vs 17 +/- 11 days and regained birth weight at 12 +/- 6 vs 13 +/- 6 days (NS). There was no difference in percent change from birth weight at 7, 14, 28, or 56 days. Treated infants had a glucose concentration of 195 +/- 60 mg/dl (10.8 +/- 3.3 mmol/L) while receiving 7.9 +/- 3.0 mg/kg/min (43 +/- 17 mumol/kg/min) of glucose at the start of insulin infusion on days 1 to 14. Insulin was given for 1 to 58 days. The initial dose was 40 to 100 mU/gm of dextrose infused (57 to 142 nmol/mol) and then gradually decreased. Less than 0.5% of blood glucose values were 25 to 40 mg/dl (1.4 to 2.2 mmol/L). We conclude that insulin infusion improves glucose tolerance in extremely low birth weight infants and allows hyperglycemic infants to achieve adequate energy intake similar to that of infants who do not become hyperglycemic.
Does the 3C (Counselling, Checking and Certification) Initiative Prevent Hypoglycemia Among At-Risk Stable Late Preterm and Term Neonates? - A Randomized Controlled Trial

Abhinavya Egala,Sindhu Sivanandan,Adhisivam Bethou

DOI: https://doi.org/10.1007/s12098-024-05138-6

2024-05-23

Abstract:Objective: To evaluate whether the 3C (Counselling, Checking, Certification) initiative helps in preventing hypoglycemia among at-risk neonates compared to standard care. Methods: This randomised controlled trial included 222 mother-newborn dyads with risk factors for neonatal hypoglycemia-Small for gestational age (SGA) babies, infants of diabetic mothers (IDM), large for gestational age (LGA) babies and late preterm infants (LPI). They were randomized to two groups. Group A received standard care while mothers in group B were administered 3C intervention. Early initiation of breastfeeding, incidence of neonatal hypoglycemia within 24 h, and exclusive breastfeeding rate at 6 mo were evaluated. Results: Early initiation of breastfeeding was higher in the 3C group compared to standard care group (94.6% vs. 55.9% p <0.001). The incidence of hypoglycemia within 24 h was lower in the intervention group compared to standard care (3.6% vs. 15.3%, p <0.05). However, there was no significant difference in exclusive breastfeeding rates at 6 mo between the two groups (61% and 66% in group A and B respectively). Conclusions: The 3C intervention decreases the incidence of hypoglycemia among at-risk neonates. Early initiation of breast-feeding is higher among mothers who receive the 3C intervention.
Neonatal hypoglycemia and neurodevelopmental outcomes: Yesterday, today, tomorrow

De Rose, Domenico Umberto

DOI: https://doi.org/10.1007/s00431-023-05405-2

IF: 2.327

2024-01-05

European Journal of Paediatric Dentistry

Abstract:Neonatal hypoglycemia is a major source of concern for pediatricians since it has commonly been related to poor neurodevelopmental outcomes. Diagnosis is challenging, considering the different operational thresholds provided by each guideline. Screening of infants at risk plays a crucial role, considering that most hypoglycemic infants show no clinical signs. New opportunities for prevention and treatment are provided by the use of oral dextrose gel. Continuous glucose monitoring systems could be a feasible tool in the next future. Furthermore, there is still limited evidence to underpin the current clinical practice of administering, in case of hypoglycemia, an intravenous "mini-bolus" of 10% dextrose before starting a continuous dextrose infusion. This brief review provides an overview of the latest advances in this field and neurodevelopmental outcomes according to different approaches. Conclusion : To adequately define if a more permissive approach is risk-free for neurodevelopmental outcomes, more research on continuous glucose monitoring and long-term follow-up is still needed. What is Known: • Neonatal hypoglycemia (NH) is a well-known cause of brain injury that could be prevented to avoid neurodevelopmental impairment. • Diagnosis is challenging, considering the different suggested operational thresholds for NH (<36, <40, <45, <47 or <50 mg/dl). What is New: • A 36 mg/dl threshold seems to be not associated with a worse psychomotor development at 18 months of life when compared to the "traditional" threshold (47 mg/dl). • Further studies on long-term neurodevelopmental outcomes are required before suggesting a more permissive management of NH.

dentistry, oral surgery & medicine,pediatrics
Effect of Glyburide vs Subcutaneous Insulin on Perinatal Complications Among Women With Gestational Diabetes: A Randomized Clinical Trial

Marie-Victoire Sénat,Helene Affres,Alexandra Letourneau,Magali Coustols-Valat,Marie Cazaubiel,Helene Legardeur,Julie Fort Jacquier,Nathalie Bourcigaux,Emmanuel Simon,Anne Rod,Isabelle Héron,Virginie Castera,Loic Sentilhes,Florence Bretelle,Catherine Rolland,Mathieu Morin,Philippe Deruelle,Celine De Carne,François Maillot,Gael Beucher,Eric Verspyck,Raoul Desbriere,Sandrine Laboureau,Delphine Mitanchez,Jean Bouyer,Groupe de Recherche en Obstétrique et Gynécologie (GROG)

DOI: https://doi.org/10.1001/jama.2018.4072

IF: 11.816

2018-05-01

JAMA

Abstract:Importance: Randomized trials have not focused on neonatal complications of glyburide for women with gestational diabetes. Objective: To compare oral glyburide vs subcutaneous insulin in prevention of perinatal complications in newborns of women with gestational diabetes. Design, settings, and participants: The Insulin Daonil trial (INDAO), a multicenter noninferiority randomized trial conducted between May 2012 and November 2016 (end of participant follow-up) in 13 tertiary care university hospitals in France including 914 women with singleton pregnancies and gestational diabetes diagnosed between 24 and 34 weeks of gestation. Interventions: Women who required pharmacologic treatment after 10 days of dietary intervention were randomly assigned to receive glyburide (n=460) or insulin (n=454). The starting dosage for glyburide was 2.5 mg orally once per day and could be increased if necessary 4 days later by 2.5 mg and thereafter by 5 mg every 4 days in 2 morning and evening doses, up to a maximum of 20 mg/d. The starting dosage for insulin was 4 IU to 20 IU given subcutaneously 1 to 4 times per day as necessary and increased according to self-measured blood glucose concentrations. Main outcomes and measures: The primary outcome was a composite criterion including macrosomia, neonatal hypoglycemia, and hyperbilirubinemia. The noninferiority margin was set at 7% based on a 1-sided 97.5% confidence interval. Results: Among the 914 patients who were randomized (mean age, 32.8 [SD, 5.2] years), 98% completed the trial. In a per-protocol analysis, 367 and 442 women and their neonates were analyzed in the glyburide and insulin groups, respectively. The frequency of the primary outcome was 27.6% in the glyburide group and 23.4% in the insulin group, a difference of 4.2% (1-sided 97.5% CI, -∞ to 10.5%; P=.19). Conclusion and relevance: This study of women with gestational diabetes failed to show that use of glyburide compared with subcutaneous insulin does not result in a greater frequency of perinatal complications. These findings do not justify the use of glyburide as a first-line treatment. Trial registration: clinicaltrials.gov Identifier: NCT01731431.
Variability in Diagnosis and Management of Hypoglycemia in Neonatal Intensive Care Unit

Daniela Dinu,Joseph L. Hagan,Paul J. Rozance

DOI: https://doi.org/10.1055/s-0044-1785491

2024-04-03

American Journal of Perinatology

Abstract:Objective Hypoglycemia, the most common metabolic derangement in the newborn period remains a contentious issue, not only due to various numerical definitions, but also due to limited therapeutical options which either lack evidence to support their efficacy or are increasingly recognized to lead to adverse reactions in this population. This study aimed to investigate neonatologists' current attitudes in diagnosing and managing transient and persistent hypoglycemia in newborns admitted to the Neonatal Intensive Care Unit (NICU). Methods A web-based electronic survey which included 34 questions and a clinical vignette was sent to U.S. neonatologists. Results There were 246 survey responses with most respondents using local protocols to manage this condition. The median glucose value used as the numerical definition of hypoglycemia in first 48 hours of life (HOL) for symptomatic and asymptomatic term infants and preterm infants was 45 mg/dL (2.5 mmol/L; 25–60 mg/dL; 1.4–3.3 mmol/L), while after 48 HOL the median value was 50 mg/dL (2.8 mmol/L; 30–70 mg/dL; 1.7–3.9 mmol/L). There were various approaches used to manage transient and persistent hypoglycemia that included dextrose gel, increasing caloric content of the feeds using milk fortifiers, using continuous feedings, formula or complex carbohydrates, and use of various medications such as diazoxide, glucocorticoids, and glucagon. Conclusion There is still large variability in current practices related to hypoglycemia. Further research is needed not only to provide evidence to support the values used as a numerical definition for hypoglycemia, but also on the efficacy of current strategies used to manage this condition. Key Points Numerical definition of glucose remains variable. Strategies managing transient and persistent hypoglycemia are diverse. There is a need for further research to investigate efficacy of various treatment options. Received: 18 January 2024 Accepted: 11 March 2024 Article published online: 02 April 2024 © 2024. Thieme. All rights reserved. Thieme Medical Publishers, Inc. 333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

pediatrics,obstetrics & gynecology
Incidence of hypoglycemia in newborn infants identified as at risk

Johanna Stark,Burkhard Simma,Anya Blassnig-Ezeh

DOI: https://doi.org/10.1080/14767058.2019.1568985

2019-01-27

Abstract:Background: Temporary low plasma glucose concentrations are common in healthy newborns. Although there is no uniform definition of neonatal hypoglycemia, there is a consensus in the current literature that plasma glucose concentrations should be measured in infants at risk. Known risk groups for transient neonatal hypoglycemia include infants of diabetic mothers (IDM), large (LGA) or small (SGA) for gestational age and late preterm (LPT) infants.Objectives: The aim of this retrospective trial was to determine the incidence of hypoglycemia and the impact of the application of a 2011 revised guideline in respect of additional feeding or i.v. glucose administration, admission to a neonatal ward and the number of blood samples taken.Methods: During the period 1 January 2015 to 31 January 2016, the plasma glucose concentrations of all infants at risk were determined. They were screened over a period of 24 hours or until plasma glucose concentration was >45 mg/dL on three occasions. Hypoglycemia was defined as a plasma glucose concentration <40 mg/dL, regardless of the age of the infant.Results: One hundred and thirty-six (13.6%) out of 1017 newborns were identified as at-risk patients, 119 (87.5%) of whom were included in the final data evaluation. Ten study participants had more than one risk factor and 32 (26.9%) newborns (male:female = 1.1:1) had a total of 40 hypoglycemic episodes. Three (9.4%) out of these 32 newborns had to be transferred to the neonatal ward for i.v. glucose treatment. The mean number of blood samples taken was 7.6 ± 2.4.Conclusions: The incidence of hypoglycemia in the studied infants at risk was 27%, and 19.7 blood samples had to be taken to detect one episode of low glucose concentration. Neonatal hypoglycemia can be recognized and avoided in time, which justifies the establishment of a standardized plasma glucose measurement protocol in newborn infants at risk.Brief RationaleFollowing a considerable number of sources, it is recommended that infants at risk be identified, low plasma glucose concentrations prevented and, if necessary, the affected neonates cared for. Our data show that the risk group for neonatal hypoglycemia comprised about one-tenth of all infants at our nursery and hypoglycemia occurred in one-fourth. These results are in accordance with the recommendations to implement this protocol as a screening tool in neonates.
Neonatal dysglycemia: a review of dysglycemia in relation to brain health and neurodevelopmental outcomes

Micheline Lagacé,Emily W Y Tam

DOI: https://doi.org/10.1038/s41390-024-03411-0

Abstract:Neonatal dysglycemia has been a longstanding interest of research in neonatology. Adverse outcomes from hypoglycemia were recognized early but are still being characterized. Premature infants additionally introduced and led the reflection on the importance of neonatal hyperglycemia. Cohorts of infants following neonatal encephalopathy provided further information about the impacts of hypoglycemia and, more recently, highlighted hyperglycemia as a central concern for this population. Innovative studies exposed the challenges of management of neonatal glycemic levels with a "u-shape" relationship between dysglycemia and adverse neurological outcomes. Lately, glycemic lability has been recognized as a key factor in adverse neurodevelopmental outcomes. Research and new technologies, such as MRI and continuous glucose monitoring, offered novel insight into neonatal dysglycemia. Combining clinical, physiological, and epidemiological data allowed the foundation of safe operational definitions, including initiation of treatment, to delineate neonatal hypoglycemia as ≤47 mg/dL, and >150-180 mg/dL for neonatal hyperglycemia. However, questions remain about the appropriate management of neonatal dysglycemia to optimize neurodevelopmental outcomes. Research collaborations and clinical trials with long-term follow-up and advanced use of evolving technologies will be necessary to continue to progress the fascinating world of neonatal dysglycemia and neurodevelopment outcomes. IMPACT STATEMENT: Safe operational definitions guide the initiation of treatment of neonatal hypoglycemia and hyperglycemia. Innovative studies exposed the challenges of neonatal glycemia management with a "u-shaped" relationship between dysglycemia and adverse neurological outcomes. The importance of glycemic lability is also being recognized. However, questions remain about the optimal management of neonatal dysglycemia to optimize neurodevelopmental outcomes. Research collaborations and clinical trials with long-term follow-up and advanced use of evolving technologies will be necessary to progress the fascinating world of neonatal dysglycemia and neurodevelopment outcomes.
Untangling the physiology and pathophysiology of neonatal hypoglycaemia

Kathryn Beardsall,Ajay Thankamony

DOI: https://doi.org/10.1136/archdischild-2024-327009

2024-10-19

Archives of Disease in Childhood - Fetal and Neonatal Edition

Abstract:Hypoglycaemia remains one of the leading causes of term admission to neonatal units. Significant time is expended by clinical teams in managing infants at risk of hypoglycaemia. Challenges remain in differentiating physiological falls in glucose concentrations from a potentially preventable cause of brain injury. The current evidence for distinguishing physiological from pathological hypoglycaemia remains limited by reliance on single point values of blood glucose (BG). Srinivasan et al 1 demonstrated a postnatal nadir in glucose concentrations, rising to values typical of older children by 48 hours of age. However, these infants were predominantly bottle fed (15% breast fed) and in a hospital nursery. In contrast, the Glucose in well babies (GLOW) study2 followed a cohort of term infants, all appropriately grown, predominantly breast feeding and at home. Uniquely, they also used both continuous glucose monitoring (CGM) and point of care (POC) measurement of alternative fuels to...

pediatrics
Approach to the Neonate with Hypoglycemia

Katherine Lord,Diva D De León

DOI: https://doi.org/10.1210/clinem/dgae267

2024-04-17

The Journal of Clinical Endocrinology & Metabolism

Abstract:Abstract After birth, healthy neonates undergo a period of altered glucose metabolism, known as “transitional hypoglycemia”. During the first 0-4 hours of life, the mean plasma glucose concentration decreases to 57 mg/dL, then by 72-96 hours of life increases to 82 mg/dL, well within the normal adult range. Recent data suggests that transitional hypoglycemia is due to persistence of the fetal beta cell’s lower threshold for insulin release, resulting in a transient hyperinsulinemic state. While hypoglycemia is an expected part of the transition to postnatal life, it makes the identification of infants with persistent hypoglycemia disorders challenging. Given the risk of neurologic injury from hypoglycemia, identifying these infants is critical. Hyperinsulinism is the most common cause of persistent hypoglycemia in neonates and infants and carries a high risk of neurocognitive dysfunction given the severity of the hypoglycemia and the inability to generate ketones, a critical alternative cerebral fuel. Screening neonates at risk for persistent hypoglycemia disorders and completing evaluations prior to hospital discharge is essential to prevent delayed diagnoses and neurologic damage.

endocrinology & metabolism
Neonates at high risk of hypoglycaemia: Is admission necessary?

Hannah M Dalrymple,Tracey Lutz,Adrienne Gordon

DOI: https://doi.org/10.1111/jpc.16132

2022-07-24

Journal of Paediatrics and Child Health

Abstract:Aim To evaluate the practice of routine admission of infants at high risk of hypoglycaemia by determining the incidence of hypoglycaemia, factors that predict necessary admission and breastfeeding outcomes. Methods A retrospective cohort study of neonates admitted to a tertiary neonatal unit for high risk of hypoglycaemia. Clinical data, including blood glucose concentrations, body fat percentage and time to initiation of feeding, were collected for 122 infant–maternal dyads for a 3‐year period from April 2016 to May 2019. Descriptive statistical analysis and binary logistic regression analysis were undertaken. Results Hypoglycaemia developed in 39.3% of the neonates identified as high risk. Overall, 69 out of 122 admissions were potentially avoidable. Initial blood glucose was the most significant predictive factor for necessary admission with odds ratio of 3.26 (95% confidence interval (CI) 1.04–10.17) for an initial glucose of 1.6–2.0 and 27.05 (95% CI 5.06–144.42) for initial glucose ≤1.5. Exclusive breastfeeding rates at discharge were lower in admitted infants (59%) compared to the overall hospital rate (75.6%). Conclusions Neonates at high risk of hypoglycaemia should be monitored with their mothers as most infants needing admission are detected by initial blood glucose concentration. This would reduce infant–maternal separation and potentially improve breastfeeding rates.

pediatrics

Oral dextrose gel for hypoglycemia in a well-baby nursery: a baby-friendly initiative

The impact of implementation of oral dextrose gel on the incidence of multiple hypoglycemia events in the well newborn nursery

Prophylactic dextrose gel use in newborns at risk for hypoglycemia

Evaluation of oral dextrose gel for prevention of neonatal hypoglycemia (hPOD): A multicenter, double-blind randomized controlled trial

Effectiveness of hospital-based oral dextrose gel in prevention and treatment of asymptomatic newborns at risk of hypoglycemia

Clinical outcomes in newborns receiving glutose 15 versus sweet cheeks oral glucose gel for neonatal hypoglycemia

Outcome at 4.5 years after dextrose gel treatment of hypoglycaemia: follow-up of the Sugar Babies randomised trial

Midwife or doctor local opinion leader to implement a national guideline in babies on postnatal wards (DesIGN): protocol of a cluster-randomised, blinded, controlled trial

Oral glucose gel in the prevention of neonatal hypoglycemia: A systematic review and meta-analysis

Dextrose gel prophylaxis for neonatal hypoglycaemia and neurocognitive function at early school age: a randomised dosage trial

Diazoxide for Severe or Recurrent Neonatal Hypoglycemia

Insulin infusion with parenteral nutrition in extremely low birth weight infants with hyperglycemia

Does the 3C (Counselling, Checking and Certification) Initiative Prevent Hypoglycemia Among At-Risk Stable Late Preterm and Term Neonates? - A Randomized Controlled Trial

Neonatal hypoglycemia and neurodevelopmental outcomes: Yesterday, today, tomorrow

Effect of Glyburide vs Subcutaneous Insulin on Perinatal Complications Among Women With Gestational Diabetes: A Randomized Clinical Trial

Variability in Diagnosis and Management of Hypoglycemia in Neonatal Intensive Care Unit

Incidence of hypoglycemia in newborn infants identified as at risk

Neonatal dysglycemia: a review of dysglycemia in relation to brain health and neurodevelopmental outcomes

Untangling the physiology and pathophysiology of neonatal hypoglycaemia

Approach to the Neonate with Hypoglycemia

Neonates at high risk of hypoglycaemia: Is admission necessary?